Cargando…

Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial

Observational studies suggest that physical activity may improve, whereas sarcopenia may worsen the survival of cancer patients. It has been suggested that secreted protein acidic and rich in cysteine (SPARC), one of the myokines that is secreted into the bloodstream by muscle contraction, has tumor...

Descripción completa

Detalles Bibliográficos
Autores principales: Akutsu, Taisuke, Ito, Eisaku, Narita, Mitsuo, Ohdaira, Hironori, Suzuki, Yutaka, Urashima, Mitsuyoshi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352842/
https://www.ncbi.nlm.nih.gov/pubmed/32512862
http://dx.doi.org/10.3390/cancers12061465
_version_ 1783557733181554688
author Akutsu, Taisuke
Ito, Eisaku
Narita, Mitsuo
Ohdaira, Hironori
Suzuki, Yutaka
Urashima, Mitsuyoshi
author_facet Akutsu, Taisuke
Ito, Eisaku
Narita, Mitsuo
Ohdaira, Hironori
Suzuki, Yutaka
Urashima, Mitsuyoshi
author_sort Akutsu, Taisuke
collection PubMed
description Observational studies suggest that physical activity may improve, whereas sarcopenia may worsen the survival of cancer patients. It has been suggested that secreted protein acidic and rich in cysteine (SPARC), one of the myokines that is secreted into the bloodstream by muscle contraction, has tumor-suppressive effects. Based on the hypothesis that serum SPARC level may be a potential prognostic biomarker, a post hoc analysis of the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2000 IU/day) in patients with stage I–III digestive tract cancer from the esophagus to the rectum (UMIN000001977) was conducted with the aim of exploring the association between serum SPARC levels after operation and survival. On multivariate analyses adjusting serum 25-hydroxyvitamin D, vitamin D supplementation, sarcopenia, body mass index, age, sex, cancer loci, stage, and adjuvant chemotherapy, patients with SPARC levels lower than the median level had a significantly higher risk for death than those with higher levels (hazard ratio, 2.25; 95% confidence interval, 1.25–4.05; p = 0.007), whereas there were no significant associations with other outcomes including recurrence. However, on the same multivariate analyses, sarcopenia was not a risk factor for death and/or relapse. These results suggest that serum SPARC levels may be a potential biomarker for death but not cancer relapse.
format Online
Article
Text
id pubmed-7352842
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-73528422020-07-15 Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial Akutsu, Taisuke Ito, Eisaku Narita, Mitsuo Ohdaira, Hironori Suzuki, Yutaka Urashima, Mitsuyoshi Cancers (Basel) Article Observational studies suggest that physical activity may improve, whereas sarcopenia may worsen the survival of cancer patients. It has been suggested that secreted protein acidic and rich in cysteine (SPARC), one of the myokines that is secreted into the bloodstream by muscle contraction, has tumor-suppressive effects. Based on the hypothesis that serum SPARC level may be a potential prognostic biomarker, a post hoc analysis of the AMATERASU randomized, double-blind, placebo-controlled trial of postoperative oral vitamin D supplementation (2000 IU/day) in patients with stage I–III digestive tract cancer from the esophagus to the rectum (UMIN000001977) was conducted with the aim of exploring the association between serum SPARC levels after operation and survival. On multivariate analyses adjusting serum 25-hydroxyvitamin D, vitamin D supplementation, sarcopenia, body mass index, age, sex, cancer loci, stage, and adjuvant chemotherapy, patients with SPARC levels lower than the median level had a significantly higher risk for death than those with higher levels (hazard ratio, 2.25; 95% confidence interval, 1.25–4.05; p = 0.007), whereas there were no significant associations with other outcomes including recurrence. However, on the same multivariate analyses, sarcopenia was not a risk factor for death and/or relapse. These results suggest that serum SPARC levels may be a potential biomarker for death but not cancer relapse. MDPI 2020-06-04 /pmc/articles/PMC7352842/ /pubmed/32512862 http://dx.doi.org/10.3390/cancers12061465 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Akutsu, Taisuke
Ito, Eisaku
Narita, Mitsuo
Ohdaira, Hironori
Suzuki, Yutaka
Urashima, Mitsuyoshi
Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
title Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
title_full Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
title_fullStr Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
title_full_unstemmed Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
title_short Effect of Serum SPARC Levels on Survival in Patients with Digestive Tract Cancer: A Post Hoc Analysis of the AMATERASU Randomized Clinical Trial
title_sort effect of serum sparc levels on survival in patients with digestive tract cancer: a post hoc analysis of the amaterasu randomized clinical trial
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7352842/
https://www.ncbi.nlm.nih.gov/pubmed/32512862
http://dx.doi.org/10.3390/cancers12061465
work_keys_str_mv AT akutsutaisuke effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial
AT itoeisaku effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial
AT naritamitsuo effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial
AT ohdairahironori effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial
AT suzukiyutaka effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial
AT urashimamitsuyoshi effectofserumsparclevelsonsurvivalinpatientswithdigestivetractcanceraposthocanalysisoftheamaterasurandomizedclinicaltrial